Please login to the form below
neurodegeneration
This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.
Lilly partners with AC Immune on tau drug for Alzheimer’s
Mark Mintun. Lilly is undeterred by those setbacks however, and Mark Mintun – the company’s vice president of neurodegeneration and pain research – said that the agreement with AC Immune “represents another
Latest news
-
Theranexus takes Alzheimer’s drug combo into clinic
While the ultimate aim of AD therapy is to develop treatments that affect the underlying cause of the neurodegeneration that leads to dementia, dozens of failed trials – particularly for anti-amyloid
-
Morning brief: New biotech launched, Merck and Moderna expand collaboration and more
Preclinical data suggest this could lead to treatments for diseases including lysosomal storage disorders, liver and muscle diseases, inflammatory disorders and neurodegeneration.
-
Axovant joins ever-growing Alzheimer’s failure club
have no effect on the underlying neurodegeneration in the disease.
-
Celgene pays $300m upfront for immunology start-up Delinia
The Delinia acquisition comes in the wake of other bolt-on deals most recently its takeover earlier this month of another immunology specialist - Anokion - and its December purchase of oncology, neurodegeneration
-
Lilly streamlines and culls leadership roles
Shaw will lead the division's focus on immunology, neurodegeneration and pain, as well as a number of the firm's already established treatments. ... Ricks added: "With new medicines recently launched - and potential new medicines in development for cancer
More from news
Approximately 1 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Key considerations for disease- modifying Parkinson’s disease trials
dopamine due to neurodegeneration.
-
Holding on to hope for Alzheimer’s advances
abnormalities including seizures, neurodegeneration, cognitive deficits and hypomyelination…it is completely unclear whether BACE could be targeted in a manner to affect amyloid processing in a therapeutic manner, without serious
-
Pharma deals in September 2015
Gencia is also at the discovery phase in mitochondrial therapies in neurodegeneration, cardiovascular disease and other areas.
-
Pharma deals during February 2014
adolescence, and ultimately neurodegeneration due to the formation of fatty yellow nodules (xanthomas) in the brain. If untreated, the disease can cause severe intellectual disability and death.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Lilly strengthens team with in-house promotions
Importantly, this team will help us maintain focus as we work to bring forward new medicines in diabetes, cancer, immunology, neurodegeneration and pain.”.
-
Asceneuron appoints chief medical officer
He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011.
-
Nouscom appoints COO and board members
Prior to this, she was the global head of neurodegeneration at Novartis, and worked in the healthcare sector of McKinsey &Company in Chicago.
-
Polleo Pharma co-founders join Chronos Therapeutics
Dr Murray (pictured above) brings over 20 years of drug discovery and early development experience to the role, spread across a range of therapeutic areas including dermatology, inflammation, neurodegeneration, psychiatry.
-
Sanofi appoints Pfizer's Rita Balice-Gordon to lead neurobiology research
including neurodegeneration, neuroinflammation and central nervous system inherited diseases.
More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
Innovative approaches in the treatment of multiple sclerosis
The pathogenesis of MS consists of two key components: focal inflammatory demyelination, and neurodegeneration.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
-
Health Consultant - Brand Comms
-
Competitive Salary
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Account Director, Medical Education
-
Salary TBC
- Senior Account Manager, Medical Communications, London
-
Excellent package
- Freelance AM/ AD Healthcare Advertising
-
£350-400 depending on experience
-
Digital Account Director
-
Salary TBC
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Scientific Director – Medical Communications
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
- Freelance Senior Account Manager / Account Director - Healthcare...
-
£350-400 depending on experience
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
Subscribe to our email news alerts
- Blood disorder specialists Imara raises $63m
- NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
- Three questions that should anchor your brand strategy
- Allergy Tx hit hard as birch pollen product stumbles
- Sanofi gets cardio outcomes claim for Praluent in EU
- Keytruda adds another NSCLC approval in Europe
PMHub
GCI Health
GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...
Latest intelligence
- “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
- The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
- The Future of Pharma sales: fast forward to 2029
- Change is inevitable, and necessary, for growth in business....
- International Women's Day - 8 March 2019
- International Women's Day has been celebrated since its inception in 1911. But how far have we come?...
Quick links
Infographics
